Olmetec (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmetec, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and is used in adults who need blood pressure control.

GNH USA supplies Olmetec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmetec is an angiotensin‑II receptor blocker indicated for conditions within the cardiovascular system where blood pressure reduction is required. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: helps delay progression of kidney damage associated with type 2 diabetes.

Adverse reactions to olmesartan are reported across a spectrum of frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevation - Bullous pemphigoid skin reaction

Olmetec should be used with attention to patient‑specific factors and monitoring requirements. - Renal impairment: adjust dose and monitor creatinine and potassium levels. - Hepatic impairment: use with caution; limited data in severe liver disease. - Concomitant diuretics: may increase risk of hypotension; monitor blood pressure. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Elderly patients: start with lower dose and titrate slowly. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan may interact with several medicines that affect the renin‑angiotensin‑aldosterone system or electrolyte balance.

Major Interactions (Avoid): - Aliskiren combined with olmesartan in patients with diabetes or renal impairment. - Potassium‑rich supplements or potassium‑sparing diuretics leading to hyper‑kalemia. - Dual blockade with ACE inhibitors or other ARBs increasing risk of renal dysfunction.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may blunt antihypertensive effect and affect kidney function. - Lithium: olmesartan can increase serum lithium levels. - Cyclosporine or tacrolimus: may raise olmesartan concentrations. - Thiazide diuretics: additive blood‑pressure lowering effect, monitor for hypotension.